Clinical Trials

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06994195 2026-04-20

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

384 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07213804 2026-04-17

FRAmework-01

1,080 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT07060807 2026-04-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

1,000 enrolled

Breast Neoplasms

NCT07214779 2026-04-16

MAESTRA 2

466 enrolled

Ovarian Neoplasms

NCT06072781 2026-04-02

RAMP 301

270 enrolled

Low Grade Serous Ovarian Cancer

NCT06312176 2026-04-02

MK-2870-010

1,200 enrolled

Phase 3 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT07286266 2026-03-19

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

450 enrolled

Ovarian Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

186 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

358 enrolled

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

340 enrolled

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT06619236 2026-03-03

RAINFOL-02

530 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07218809 2026-01-16

TREVI-OC-01

1,100 enrolled

Carcinoma, Ovarian Epithelial

NCT05092360 2025-08-28

ARTISTRY-7

456 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04209855 2025-08-27

MIRASOL

453 enrolled 18 charts 2 FDA

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02584478 2023-11-08

AL3818

Phase 3 Unknown

294 enrolled

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02580058 2023-07-10

JAVELIN Ovarian 200

566 enrolled 40 charts

Ovarian Neoplasms

NCT00976911 2022-06-21

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

361 enrolled 15 charts

Ovarian Neoplasms

NCT01170650 2021-09-30

PROCEED

441 enrolled

Neoplasms, Ovarian Neoplasms

NCT02631876 2020-10-14

FORWARD I

366 enrolled 20 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02421588 2020-04-03

CORAIL

442 enrolled 33 charts

Ovarian Neoplasms

NCT01846611 2019-04-01

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

581 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00266799 2017-06-08

The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)

210 enrolled 11 charts

Breast Neoplasms

NCT00097981 2017-04-07

A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

225 enrolled 14 charts

Plasma cell

Multiple Myeloma

NCT01840943 2015-12-23

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

32 enrolled 13 charts

Carcinoma, Ovarian Epithelial, Carcinoma, Neoplasms, Ovarian Neoplasms

NCT00103506 2015-10-19

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

646 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT00082095 2014-10-09

To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

62 enrolled

Breast Neoplasms

NCT00113607 2014-06-27

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

672 enrolled 14 charts

Ovarian Neoplasms

NCT00091442 2014-04-21

A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

751 enrolled 10 charts

Breast Neoplasms

NCT00350948 2013-11-27

ASSIST-5

244 enrolled

Ovarian Neoplasms

NCT00344422 2011-06-10

Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

198 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00653952 2010-04-27

CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

220 enrolled

Ovarian Neoplasms

NCT00191607 2007-01-26

A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

162 enrolled